

MD7005/MD7255 - Advanced Injectable Therapies

Advanced Injectable Therapies

View Online



1.
Richard I. G. Holt, , Clive Cockram, , Allan Flyvbjerg, , and Barry J. Goldstein: Textbook of Diabetes. John Wiley & Sons, Incorporated (2016).

2.
Gururaj Setty, S., Crasto, W., Jarvis, J., Khunti, K., Davies, M.J.: New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. *Postgraduate Medical Journal*. 92, 152–164 (2016).
<https://doi.org/10.1136/postgradmedj-2015-133716>.

3.
Daly, H., Davies, M., Barnett, J., Amin, S., Gray, G., Leonard, J., Northern, A., Crasto, W., Khunti, K., Jarvis, J.: Development of a self-management education module for those with type 2 diabetes on injectable therapies. *Practical Diabetes*. 32, 305–310a (2015).
<https://doi.org/10.1002/pdi.1979>.

4.
Ajikumar B Aryangat, John E Gerich: Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. *Vascular Health and Risk Management*. 6, (2010).

5.
Ashwell, S.G., Amiel, S.A., Bilous, R.W., Dashora, U., Heller, S.R., Hepburn, D.A., Shutler, S.D., Stephens, J.W., Home, P.D.: Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. *Diabetic Medicine*. 23, 285–292 (2006). <https://doi.org/10.1111/j.1464-5491.2005.01781.x>.

6.

Bretzel, R.G., Nuber, U., Landgraf, W., Owens, D.R., Bradley, C., Linn, T.: Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. *The Lancet*. 371, 1073–1084 (2008). [https://doi.org/10.1016/S0140-6736\(08\)60485-7](https://doi.org/10.1016/S0140-6736(08)60485-7).

7.

Carver, C.: Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes. *The Diabetes Educator*. 32, 910–917 (2006). <https://doi.org/10.1177/0145721706294259>.

8.

Sharon Allard, Caroline Butler, Sue Cradock, Heather Daly, Jemma Edwards, Elizabeth Gilbert: Using Conversation Maps in practice: the UK experience. *Journal of Diabetes Nursing*. 14, (2010).

9.

Davies, M.J., Donnelly, R., Barnett, A.H., Jones, S., Nicolay, C., Kilcoyne, A.: Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. *Diabetes, Obesity and Metabolism*. 11, 1153–1162 (2009). <https://doi.org/10.1111/j.1463-1326.2009.01154.x>.

10.

Davies, M.J., Donnelly, R., Barnett, A.H., Jones, S., Nicolay, C., Kilcoyne, A.: Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. *Diabetes, Obesity and Metabolism*. 11, 1153–1162 (2009). <https://doi.org/10.1111/j.1463-1326.2009.01154.x>.

11.

Funnell, M.M.: Overcoming Barriers to the Initiation of Insulin Therapy. *Clinical Diabetes*. 25, 36–38 (2007). <https://doi.org/10.2337/diaclin.25.1.36>.

12.

Garber, A.J., Wahlen, J., Wahl, T., Bressler, P., Braceras, R., Allen, E., Jain, R.: Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). *Diabetes, Obesity and Metabolism*. 8, 58–66 (2006). <https://doi.org/10.1111/j.1463-1326.2005.00563.x>.

13.

Gough, S.C.L.: A review of human and analogue insulin trials. *Diabetes Research and Clinical Practice*. 77, 1–15 (2007). <https://doi.org/10.1016/j.diabres.2006.10.015>.

14.

Garber, A.J., Ligthelm, R., Christiansen, J.S., Liebl, A.: Premixed insulin treatment for type 2 diabetes: analogue or human? *Diabetes, Obesity and Metabolism*. 9, 630–639 (2007). <https://doi.org/10.1111/j.1463-1326.2006.00654.x>.

15.

Heller, S.R., Colagiuri, S., Vaaler, S., Wolffenbuttel, B.H.R., Koelendorf, K., Friberg, H.H., Windfeld, K., Lindholm, A.: Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. *Diabetic Medicine*. 21, 769–775 (2004). <https://doi.org/10.1111/j.1464-5491.2004.01244.x>.

16.

Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P.: A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. *Diabetes Care*. 29, 1269–1274 (2006). <https://doi.org/10.2337/dc05-1365>.

17.

Holman, R.R., Thorne, K.I., Farmer, A.J., Davies, M.J., Keenan, J.F., Paul, S., Levy, J.C.: Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. *New England Journal of Medicine*. 357, 1716–1730 (2007). <https://doi.org/10.1056/NEJMoa075392>.

18.

Holman, R.R., Turner, R.C.: A Practical Guide to Basal and Prandial Insulin Therapy. *Diabetic Medicine*. 2, 45–53 (1985). <https://doi.org/10.1111/j.1464-5491.1985.tb00592.x>.

19.

Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S.H., Gratzner, T.W., Plank, J., Kaiser, T., Pieber, T.R., Siebenhofer, A.: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In: *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd, Chichester, UK (1996). <https://doi.org/10.1002/14651858.CD005613.pub3>.

20.

Mäkimmattila, S., Nikkilä, K., Yki-Järvinen, H.: Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. *Diabetologia*. 42, 406–412 (1999). <https://doi.org/10.1007/s001250051172>.

21.

Malmberg, K.: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. *BMJ*. 314, 1512–1512 (1997). <https://doi.org/10.1136/bmj.314.7093.1512>.

22.

Ismail-Beigi, F.: Glycemic Management of Type 2 Diabetes Mellitus. *New England Journal of Medicine*. 366, 1319–1327 (2012). <https://doi.org/10.1056/NEJMcp1013127>.

23.

Nathan, D.M., Buse, J.B., Davidson, M.B., Heine, R.J., Holman, R.R., Sherwin, R., Zinman, B.: Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 29, 1963–1972 (2006). <https://doi.org/10.2337/dc06-9912>.

24.

Marre, M., Shaw, J., Brändle, M., Bebakar, W.M.W., Kamaruddin, N.A., Strand, J.,

Zdravkovic, M., Le Thi, T.D., Colagiuri, S.: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). *Diabetic Medicine*. 26, 268–278 (2009). <https://doi.org/10.1111/j.1464-5491.2009.02666.x>.

25.

Hirsch, I.B., Buse, J.B., Leahy, J., McGill, J.B., Peters, A., Rodbard, H.W., Rubin, R.R., Skyler, J.S., Verderese, C.A., Riddle, M.C.: Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. *Diabetes, Obesity and Metabolism*. 16, 206–214 (2014). <https://doi.org/10.1111/dom.12136>.

26.

Srinivasan, B.T., Davies, M.: Glycaemic management of type 2 diabetes. *Medicine*. 42, 711–717 (2014). <https://doi.org/10.1016/j.mpmed.2014.09.011>.

27.

Young, L.A., Buse, J.B.: GLP-1 receptor agonists and basal insulin in type 2 diabetes. *The Lancet*. 384, 2180–2181 (2014). [https://doi.org/10.1016/S0140-6736\(14\)61409-4](https://doi.org/10.1016/S0140-6736(14)61409-4).

28.

Bergenstal, R.M., Tamborlane, W.V., Ahmann, A., Buse, J.B., Dailey, G., Davis, S.N., Joyce, C., Peoples, T., Perkins, B.A., Welsh, J.B., Willi, S.M., Wood, M.A.: Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. *New England Journal of Medicine*. 363, 311–320 (2010). <https://doi.org/10.1056/NEJMoa1002853>.

29.

Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., Trautmann, M.: Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *The Lancet*. 375, 2234–2243 (2010). [https://doi.org/10.1016/S0140-6736\(10\)60406-0](https://doi.org/10.1016/S0140-6736(10)60406-0).

30.

Gururaj Setty, S., Crasto, W., Jarvis, J., Khunti, K., Davies, M.J.: New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. *Postgraduate Medical Journal*. 92, 152–164 (2016).
<https://doi.org/10.1136/postgradmedj-2015-133716>.

31.

Rosenstock, J., Raccach, D., Koranyi, L., Maffei, L., Boka, G., Miossec, P., Gerich, J.E.: Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). *Diabetes Care*. 36, 2945–2951 (2013).
<https://doi.org/10.2337/dc12-2709>.

32.

Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., Weitgasser, R.: Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. *The Lancet*. 388, 2254–2263 (2016).
[https://doi.org/10.1016/S0140-6736\(16\)31535-5](https://doi.org/10.1016/S0140-6736(16)31535-5).

33.

Khunti, K., Davies, M., Majeed, A., Thorsted, B.L., Wolden, M.L., Paul, S.K.: Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. *Diabetes Care*. 38, 316–322 (2015).
<https://doi.org/10.2337/dc14-0920>.

34.

Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A.L., Tsapas, A., Wender, R., Matthews, D.R.: Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 38, 140–149 (2015). <https://doi.org/10.2337/dc14-2441>.

35.

Htike, Z.Z., Zaccardi, F., Papamargaritis, D., Webb, D.R., Khunti, K., Davies, M.J.: Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. *Diabetes, Obesity and Metabolism*. (2017). <https://doi.org/10.1111/dom.12849>.

36.

Evans, M., Schumm-Draeger, P.M., Vora, J., King, A.B.: A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. *Diabetes, Obesity and Metabolism*. 13, 677–684 (2011). <https://doi.org/10.1111/j.1463-1326.2011.01395.x>.

37.

Nauck, M.: Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. *Diabetes, Obesity and Metabolism*. 18, 203–216 (2016). <https://doi.org/10.1111/dom.12591>.

38.

Srinivasan, B.T., Jarvis, J., Khunti, K., Davies, M.J.: Recent advances in the management of type 2 diabetes mellitus: a review. *Postgraduate Medical Journal*. 84, 524–531 (2008). <https://doi.org/10.1136/pgmj.2008.067918>.

39.

Home, P.D.: The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. *Diabetes, Obesity and Metabolism*. 14, 780–788 (2012). <https://doi.org/10.1111/j.1463-1326.2012.01580.x>.

40.

June James: Safety and insulin: implementation of national guidance at a local level. *Journal of diabetes nursing*.

41.

Rorsman, P., Renström, E.: Insulin granule dynamics in pancreatic beta cells. *Diabetologia*. 46, 1029–1045 (2003). <https://doi.org/10.1007/s00125-003-1153-1>.

42.

L. Luzi: Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. *American Journal of Physiology - Endocrinology and Metabolism*. 257, E241–E246 (1989).

43.

Luc JC van Loon: Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. *The American Journal of Clinical Nutrition*. 72, 96–105 (2000).

44.

Menting, J.G., Whittaker, J., Margetts, M.B., Whittaker, L.J., Kong, G.K.-W., Smith, B.J., Watson, C.J., Žáková, L., Kletvíková, E., Jiráček, J., Chan, S.J., Steiner, D.F., Dodson, G.G., Brzozowski, A.M., Weiss, M.A., Ward, C.W., Lawrence, M.C.: How insulin engages its primary binding site on the insulin receptor. *Nature*. 493, 241–245 (2013). <https://doi.org/10.1038/nature11781>.

45.

Wahren, J., Kallas, A.: Loss of Pulsatile Insulin Secretion: A Factor in the Pathogenesis of Type 2 Diabetes? *Diabetes*. 61, 2228–2229 (2012). <https://doi.org/10.2337/db12-0664>.

46.

Richter, B., Neises, G.: 'Human' insulin versus animal insulin in people with diabetes mellitus. In: *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd, Chichester, UK (1996). <https://doi.org/10.1002/14651858.CD003816.pub2>.

47.

Crasto, W., Jarvis, J., Hackett, E., Nayyar, V., McNally, P.G., Davies, M.J., Lawrence, I.G.: Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. *Postgraduate Medical Journal*. 85, 219–222 (2009). <https://doi.org/10.1136/pgmj.2008.073379>.

48.

Swinnen, S.G., Simon, A.C., Holleman, F., Hoekstra, J.B., DeVries, J.H.: Insulin detemir versus insulin glargine for type 2 diabetes mellitus. In: *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd, Chichester, UK (1996).

<https://doi.org/10.1002/14651858.CD006383.pub2>.

49.

Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., Hänninen, J., Levänen, H., Lahdenperä, S., Lehtonen, R., Ryysy, L.: Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. *Diabetologia*. 49, 442–451 (2006). <https://doi.org/10.1007/s00125-005-0132-0>.

50.

Riddle, M.C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., Rosenstock, J.: Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin. *Diabetes Care*. 36, 2489–2496 (2013). <https://doi.org/10.2337/dc12-2454>.

51.

Gough, S.C.L., Bhargava, A., Jain, R., Mersebach, H., Rasmussen, S., Bergenstal, R.M.: Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes. *Diabetes Care*. 36, 2536–2542 (2013). <https://doi.org/10.2337/dc12-2329>.

52.

Hirsch, I.B., Buse, J.B., Leahy, J., McGill, J.B., Peters, A., Rodbard, H.W., Rubin, R.R., Skyler, J.S., Verderese, C.A., Riddle, M.C.: Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. *Diabetes, Obesity and Metabolism*. 16, 206–214 (2014). <https://doi.org/10.1111/dom.12136>.

53.

Zinman, B., Fulcher, G., Rao, P.V., Thomas, N., Endahl, L.A., Johansen, T., Lindh, R., Lewin, A., Rosenstock, J., Pinget, M., Mathieu, C.: Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. *The Lancet*. 377, 924–931 (2011). [https://doi.org/10.1016/S0140-6736\(10\)62305-7](https://doi.org/10.1016/S0140-6736(10)62305-7).

54.

Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S.H., Gratzner, T.W., Plank, J., Kaiser, T., Pieber, T.R., Siebenhofer, A.: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, Chichester, UK (1996).
<https://doi.org/10.1002/14651858.CD005613.pub3>.

55.

Buse, J.B., Bergenstal, R.M., Glass, L.C., Heilmann, C.R., Lewis, M.S., Kwan, A.Y.M., Hoogwerf, B.J., Rosenstock, J.: Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes. *Annals of Internal Medicine*. 154, (2011).
<https://doi.org/10.7326/0003-4819-154-2-201101180-00300>.

56.

Rosenstock, J., Jelaska, A., Frappin, G., Salsali, A., Kim, G., Woerle, H.J., Broedl, U.C.: Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. *Diabetes Care*. 37, 1815–1823 (2014).
<https://doi.org/10.2337/dc13-3055>.

57.

Frandsen, C.S.S., Madsbad, S.: Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. *Diabetic Medicine*. 31, 1293–1300 (2014). <https://doi.org/10.1111/dme.12561>.

58.

Hirsch, I.B., Franek, E., Mersebach, H., Bardtrum, L., Hermansen, K.: Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST T1). *Diabetic Medicine*. 34, 167–173 (2017).
<https://doi.org/10.1111/dme.13068>.

59.

Rodbard, H.W., Bode, B.W., Harris, S.B., Rose, L., Lehmann, L., Jarlov, H., Thurman, J.: Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL

IV trial. *Diabetic Medicine*. 34, 189–196 (2017). <https://doi.org/10.1111/dme.13256>.

60.

Rosenstock, J., Davies, M., Home, P.D., Larsen, J., Koenen, C., Schernthaner, G.: A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. *Diabetologia*. 51, 408–416 (2008). <https://doi.org/10.1007/s00125-007-0911-x>.

61.

Raskin, P., Allen, E., Hollander, P., Lewin, A., Gabbay, R.A., Hu, P., Bode, B., Garber, A.: Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs. *Diabetes Care*. 28, 260–265 (2005). <https://doi.org/10.2337/diacare.28.2.260>.

62.

Davies, M., Storms, F., Shutler, S., Bianchi-Biscay, M., Gomis, R.: Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. *Diabetes Care*. 28, 1282–1288 (2005). <https://doi.org/10.2337/diacare.28.6.1282>.

63.

Pickup, J.C., Reznik, Y., Sutton, A.J.: Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials. *Diabetes Care*. 40, 715–722 (2017). <https://doi.org/10.2337/dc16-2201>.

64.

Davies, M.J., Leiter, L.A., Guerci, B., Grunberger, G., Ampudia-Blasco, F.J., Yu, C., Stager, W., Niemoeller, E., Souhami, E., Rosenstock, J.: Impact of baseline HbA1c, diabetes duration and BMI on clinical outcomes in the LixiLan-O trial testing iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine and lixisenatide monocomponents. *Diabetes, Obesity and Metabolism*. (2017). <https://doi.org/10.1111/dom.12980>.

65.

Raccah, D., Huet, D., Dib, A., Joseph, F., Landers, B., Escalada, J., Schmitt, H.: Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. *Diabetic Medicine*. (2017). <https://doi.org/10.1111/dme.13390>.

66.

Marso, S.P., McGuire, D.K., Zinman, B., Poulter, N.R., Emerson, S.S., Pieber, T.R., Pratley, R.E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., Moses, A., Skibsted, S., Kvist, K., Buse, J.B.: Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. *New England Journal of Medicine*. (2017). <https://doi.org/10.1056/NEJMoa1615692>.

67.

Wang, W., Liu, H., Xiao, S., Liu, S., Li, X., Yu, P.: Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. *Diabetes Therapy*. (2017). <https://doi.org/10.1007/s13300-017-0282-3>.

68.

Villani, M., de Courten, B., Zoungas, S.: Emergency treatment of hypoglycaemia: a guideline and evidence review. *Diabetic Medicine*. 34, 1205–1211 (2017). <https://doi.org/10.1111/dme.13379>.

69.

Leelarathna, L., Roberts, S.A., Hindle, A., Markakis, K., Alam, T., Chapman, A., Morris, J., Urwin, A., Jinadev, P., Rutter, M.K.: Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes. *Diabetic Medicine*. 34, 1372–1379 (2017). <https://doi.org/10.1111/dme.13412>.

70.

Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. - PubMed - NCBI, <http://www.ncbi.nlm.nih.gov/pubmed/18715200>.

71.

New IDegLira data show rapid and predictable glycaemic improvements in people with

type 2 diabetes,
<http://www.multivu.com/players/English/72762519-novo-nordisk-IDegLira-treatment/>.

72.

Anderson, B., Funnell, M., American Diabetes Association: The art of empowerment: stories and strategies for diabetes educators. American Diabetes Association, Alexandria, Va (2005).

73.

MacKinnon, M.: Providing diabetes care in general practice: a practical guide to integrated care. Class, London (2002).

74.

Walker, R.A., Rodgers, J., Diabetes UK.: Diabetes: a practical guide to managing your health. Dorling Kindersley, London (2010).

75.

Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes,
<https://www.youtube.com/watch?v=AhhWTmEFuag>, (4)AD.

76.

Raccah, D., Huet, D., Dib, A., Joseph, F., Landers, B., Escalada, J., Schmitt, H.: Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabetic Medicine. 34, 1193-1204 (2017).
<https://doi.org/10.1111/dme.13390>.